Toward Eliminating Poliovirus—In the Lab

As the world inches closer to polio eradication, laboratories studying the virus will have to bolster biosafety standards. Eventually, most will need to stop working with the pathogen entirely.

Written byRina Shaikh-Lesko
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Electron micrograph of poliovirusWIKIMEDIA, CDCIn September, the Global Polio Eradication Initiative (GPEI) declared type 2 poliovirus eradicated. This long-awaited statement officially confirmed what polio researchers and global public health officials had known for more than a decade: one of the triumvirate of polioviruses was no longer a threat. The last case of type 2 poliovirus was diagnosed in Northern India in 1999.

The announcement also set in motion a critical component of the GPEI’s Poliovirus Eradication Endgame Strategic Plan. Among other things, public health officials are planning to stop using oral polio vaccine against type 2 poliovirus in April 2016. To reduce risk of accidental release, all laboratories that stock type 2 poliovirus—both the wild-type and vaccine virus—will need to destroy the virus soon after that date, or adopt stricter standards for handling it.

Containment of type 2 poliovirus, “really is a step forward to containment of type 1 and 3,” said Walter Dowdle, a consultant to the Task Force for Global Health and former deputy director of the US Centers for Disease Control and Prevention (CDC).

This transition for handling laboratory stocks of type 2 poliovirus ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies